Out of a total of 19 treated patients, a total of two objective responses were observed: a partial response (PR) in a patient with NSCLC and HER2 mutation (G788_P780dup) treated at 50 mg BID and a PR in a patient with biliary tract cancer (BTC) with HER2 amplification confirmed by FISH treated at 200 mg BID. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.